Key result
Cardiac resynchronization therapy is evolving with new developments in lead technology, imaging, and leadless systems to address the up to 30% non-response rate in heart failure patients.
New developments in cardiac resynchronization therapy, such as quadripolar leads, endocardial pacing, and leadless systems, offer potential solutions to overcome the 30% non-response rate and anatomical challenges of traditional transvenous left ventricular lead implantation.
Answers are grounded in this paper and cite their sources.
New CRT technologies merit prospective trials; evidence leaves open their effect on non-response rates.
Cardiac resynchronization therapy significantly reduces mortality and morbidity in patients with heart failure and ventricular dyssynchrony. This is a dynamic field with some exciting recent advances, and these future directions are discussed in this review.
No takes yet. Share an insight, caveat, or question.
Sankaranarayanan et al. (2013) conducted a review in Heart failure with ventricular dyssynchrony. Cardiac resynchronization therapy (CRT) and novel device technologies was evaluated. Cardiac resynchronization therapy is evolving with new developments in lead technology, imaging, and leadless systems to address the up to 30% non-response rate in heart failure patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: